Atai Life Sciences (NasdaqGM:ATAI) Update / briefing Transcript

Summary of Atai Life Sciences Conference Call on EMP-01 Phase 2A Results Company Overview - Company: Atai Life Sciences (NasdaqGM: ATAI) - Product: EMP-01, an oral R-MDMA candidate for treating social anxiety disorder (SAD) Key Industry Insights - Social Anxiety Disorder (SAD): - Affects hundreds of millions globally, with nearly 60% of patients receiving no treatment [4][5] - Current treatments (SSRIs/SNRIs) have not seen innovation in over 20 years, often requiring daily dosing and taking months to show benefits [5] - High unmet need for treatments that act more rapidly and can be administered intermittently [5] Core Findings from Phase 2A Trial - Study Design: - Randomized, placebo-controlled trial with 70 patients [7][8] - Two doses of EMP-01 (225 mg) administered at day 1 and day 29, with endpoints assessed at day 43 [8][9] - Focused on safety, tolerability, feasibility, and early efficacy signals [6][9] - Efficacy Results: - LSAS (Liebowitz Social Anxiety Scale) showed a least squared mean treatment difference of 11.85 points, with a standardized effect size of 0.45 [20] - Nearly 50% of patients in the EMP group were deemed responders on the Clinical Global Impression of Improvement (CGI-I) scale, compared to 14% in the placebo group [22][23] - Number needed to treat (NNT) was less than 3, indicating a favorable response rate compared to other treatments [23] - Safety Profile: - Adverse events were mild to moderate, with no severe or serious adverse events reported [13][14] - No suicidal intent or behavior was reported during the study [14] - Common adverse events included nausea, headache, and fatigue, consistent with the psychedelic experience [15] Additional Insights - Patient Population: - High baseline LSAS score of 108, indicating a severely impaired group [12] - Approximately 50% of participants had previously tried other medications for SAD, highlighting treatment resistance [67] - Behavioral Change: - EMP-01 showed potential for reducing both fear and avoidance behaviors simultaneously, which is a unique finding compared to traditional treatments [90] - The study suggests that EMP-01 may influence core learning or behavioral extinction mechanisms rather than just anxiety [87] - Future Directions: - Plans for further analysis and potential Phase 2B or Phase 3 trials, with considerations for dose ranging and the number of doses [38][104] - Discussion on the possibility of conducting trials without therapy components to assess the drug's efficacy independently [97] - Statistical Considerations: - The study utilized a one-tailed p-value for statistical significance, which may have implications for interpreting results compared to a two-tailed test [106][108] Conclusion - The exploratory Phase 2A trial of EMP-01 in treating social anxiety disorder has shown promising early results in terms of safety and efficacy, addressing a significant unmet need in the treatment landscape. Further studies are planned to refine dosing strategies and assess long-term efficacy.